| Hemolysis events in the phase 3 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria.Blood Adv | PMID 38593241PMC11170155 | 2024-Jun-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Longitudinal neurofunctional changes in medication overuse headache patients after mindfulness practice in a randomized controlled trial (the MIND-CM study).J Headache Pain | PMID 38858629PMC11165872 | 2024-Jun-11 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.J Clin Oncol | PMID 38382001PMC11185916 | 2024-Jun-10 | 1.00 | 命中用户提供的消化道肿瘤阳性参考集。 | 待处理 |
| Nurse-Led Individualized Follow-Up Versus Regular Physician-Led Visits After Early Breast Cancer (MyHealth): A Phase III Randomized, Controlled Trial.J Clin Oncol | PMID 38498781无 PMCID | 2024-Jun-10 | 0.95 | The trial is a Phase III randomized oncology study with original results, but it evaluates a non-drug, nurse-led intervention (behavioral/management) and its primary endpoint is quality of life, not a time-to-event efficacy endpoint like OS, PFS, DFS, EFS, RFS, or TTP. | 待处理 |
| Reduced-Volume Irradiation of Uninvolved Neck in Patients With Nasopharyngeal Cancer: Updated Results From an Open-Label, Noninferiority, Multicenter, Randomized Phase III Trial.J Clin Oncol | PMID 38507662无 PMCID | 2024-Jun-10 | 0.95 | The trial is eligible in terms of oncology, human, randomized, phase, time-to-event endpoint, and being an original result report. However, it is excluded because it does not involve a drug-containing intervention. The study compares two radiation therapy regimens for the uninvolved neck, which is a non-drug intervention. | 待处理 |
| Randomized, Double-Blind Phase III Study of Pazopanib Versus Placebo in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy: ECOG-ACRIN E2810.J Clin Oncol | PMID 38531002PMC11514296 | 2024-Jun-10 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials.Lancet | PMID 38795716无 PMCID | 2024-Jun-08 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Effect of Non-Rotavirus Enteric Infections on Vaccine Efficacy in a ROTASIIL Clinical Trial.Am J Trop Med Hyg | PMID 38626750PMC11154053 | 2024-Jun-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Long-acting cabotegravir pharmacokinetics with and without oral lead-in for HIV PrEP.Antimicrob Agents Chemother | PMID 38709006PMC11620484 | 2024-Jun-05 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Ponatinib vs Imatinib in Frontline Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.JAMA | PMID 38722621PMC11082750 | 2024-Jun-04 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Efficacy and Safety of Ongericimab in Chinese Patients With Primary Hypercholesterolemia and Mixed Dyslipidemia.J Am Heart Assoc | PMID 38818934PMC11255649 | 2024-Jun-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies.RMD Open | PMID 38834351PMC11163688 | 2024-Jun-04 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of Concomitant Thiopurine on the Efficacy and Safety of Filgotinib in Patients with Ulcerative Colitis: Post Hoc Analysis of the Phase 2b/3 SELECTION Study.J Crohns Colitis | PMID 38019901PMC11147794 | 2024-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies.J Crohns Colitis | PMID 38069472PMC11147806 | 2024-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| The Relationship Between Health-Related Quality of Life and Overall Survival in Patients With Advanced Renal Cell Carcinoma in CheckMate 214.Oncologist | PMID 38280218PMC11144972 | 2024-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma.Clin Cancer Res | PMID 38324398无 PMCID | 2024-Jun-03 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Linzagolix therapy versus a placebo in patients with endometriosis-associated pain: a prospective, randomized, double-blind, Phase 3 study (EDELWEISS 3).Hum Reprod | PMID 38648863PMC11144970 | 2024-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Peceleganan Spray for the Treatment of Skin Wound Infections: A Randomized Clinical Trial.JAMA Netw Open | PMID 38861260PMC11167495 | 2024-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Riluzole for Degenerative Cervical Myelopathy: A Secondary Analysis of the CSM-PROTECT Trial.JAMA Netw Open | PMID 38904964PMC11193126 | 2024-Jun-03 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Impact of mild thrombocytopenia on bleeding and recurrent thrombosis in cancer.Haematologica | PMID 37855029PMC11141682 | 2024-Jun-01 | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Mepolizumab improves sense of smell in severe chronic rhinosinusitis with nasal polyps: SYNAPSE.Rhinology | PMID 38217844无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy of a new water-free topical cyclosporine 0.1% solution for optimizing the ocular surface in patients with dry eye and cataract.J Cataract Refract Surg | PMID 38334413PMC11146174 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Outcomes of patients enrolled in a prospective and randomized trial on basis of gestalt assessment or ABC score.J Trauma Acute Care Surg | PMID 38342992无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy.AIDS | PMID 38349226PMC11064918 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia.Haematologica | PMID 38385304PMC11141665 | 2024-Jun-01 | 0.99 | 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 | 待处理 |
| Phase 3 Safety and Immunogenicity Study of a Three-dose Series of Twenty-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers.Pediatr Infect Dis J | PMID 38456705PMC11090518 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| LetibotulinumtoxinA Attenuates the Psychological Burden of Glabellar Lines and Is Associated With High Subject Satisfaction in Phase 3 Clinical Trials.Dermatol Surg | PMID 38470985无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Preservative-Free Bimatoprost 0.01% Ophthalmic Gel for Glaucoma Therapy: A Phase III Randomized Controlled Trial.J Glaucoma | PMID 38506750PMC11146180 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of PrabotulinumtoxinA in Subjects With Benign Masseteric Hypertrophy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase 3 Trial and Open-Label Extension Study.Dermatol Surg | PMID 38518110无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| A Phase Three Study of the Safety and Immunogenicity of a Four-dose Series of 20-Valent Pneumococcal Conjugate Vaccine in Healthy Infants.Pediatr Infect Dis J | PMID 38535409PMC11090512 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Adjuvant Transarterial Chemoembolization With Sorafenib for Portal Vein Tumor Thrombus: A Randomized Clinical Trial.JAMA Surg | PMID 38568599PMC10993157 | 2024-Jun-01 | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Treating moderate-to-severe menopausal vasomotor symptoms with fezolinetant: analysis of responders using pooled data from two phase 3 studies (SKYLIGHT 1 and 2).Menopause | PMID 38626380无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.Menopause | PMID 38652875无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pegcetacoplan Treatment and Consensus Features of Geographic Atrophy Over 24 Months.JAMA Ophthalmol | PMID 38722644PMC11082756 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence.Hepatol Commun | PMID 38727685PMC11093560 | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Rebamipide gargle and benzydamine gargle in prevention and management of chemo-radiotherapy and radiotherapy-induced oral mucositis in head and neck cancer patients (randomized clinical trial).BMC Oral Health | PMID 38824583PMC11143556 | 2024-Jun-01 | 0.95 | The record describes a Phase III randomized trial of drug interventions in head and neck cancer, but the primary outcome is the incidence and characteristics of oral mucositis (a treatment side effect), not a time-to-event efficacy endpoint. Therefore, it does not meet the requirement for a primary/key secondary time-to-event efficacy endpoint. | 待处理 |
| Triple-Combination Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Acne in Adult and Pediatric Participants.J Drugs Dermatol | PMID 38834226无 PMCID | 2024-Jun-01 | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Aldosterone synthase inhibitor (BI 690517) therapy for people with diabetes and albuminuric chronic kidney disease: A multicentre, randomized, double-blind, placebo-controlled, Phase I trial.Diabetes Obes Metab | PMID 38497241无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials.Cardiovasc Drugs Ther | PMID 36550348PMC11101568 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| COMfort Eye Trial (COMET) results - a non-inferiority, randomized, investigator-masked, two-parallel group, phase III clinical trial, to evaluate the efficacy and safety of a preservative free formulation of latanoprost versus a reference drug (Xalatan®) in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT).Expert Opin Drug Saf | PMID 37674345无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Mechanistic Evaluation of Diffusion Weighted Hyperintense Lesions After Large Spontaneous Intracerebral Hemorrhage: A Subgroup Analysis of MISTIE III.Neurocrit Care | PMID 38040993无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial.Clin Transl Oncol | PMID 38102374PMC11108865 | 2024-Jun | 0.96 | 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 | 待处理 |
| Comparative assessment of immunogenicity of recombinant insulin Aspart from BioGenomics and its originator NovoRapid® in adult patients with type 2 diabetes mellitus.J Endocrinol Invest | PMID 38147290无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand.J Infect Chemother | PMID 38154616无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Faricimab Treat-and-Extend for Diabetic Macular Edema: Two-Year Results from the Randomized Phase 3 YOSEMITE and RHINE Trials.Ophthalmology | PMID 38158159无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.J Thorac Oncol | PMID 38159809无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |
| Systemic exposure to aflibercept after intravitreal injection in premature neonates with retinopathy of prematurity: results from the FIREFLEYE randomized phase 3 study.Eye (Lond) | PMID 38200320PMC11126565 | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial.J Am Acad Dermatol | PMID 38266683无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Efficacy and safety of piclidenoson in plaque psoriasis: Results from a randomized phase 3 clinical trial (COMFORT-1).J Eur Acad Dermatol Venereol | PMID 38279575无 PMCID | 2024-Jun | 0.98 | 未发现恶性肿瘤人群证据。 | 待处理 |
| Iruplinalkib (WX-0593) Versus Crizotinib in ALK TKI-Naive Locally Advanced or Metastatic ALK-Positive NSCLC: Interim Analysis of a Randomized, Open-Label, Phase 3 Study (INSPIRE).J Thorac Oncol | PMID 38280448无 PMCID | 2024-Jun | 0.98 | 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 | 待处理 |